ClinicalTrials.gg
CompletedNCT01523041Updated Feb 24, 2017

Comparison of Two Formulations of Biphasic Insulin Aspart 70

A Phase 1 interventional study of biphasic insulin aspart 70 and biphasic insulin aspart 70 in Diabetes and Healthy, sponsored by Novo Nordisk A/S. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2017-02-24.

Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 12 years 2 months after the study started (first participant enrolled Nov 1999, registered Jan 2012).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 142 studies testing Insulin Aspart in Diabetes Mellitus — 1 open to participants now, 1 under way, 1 of them phase 3. Insulin Aspart · Diabetes Mellitus.

Enrollment
121st of 142
24 · median 80
Started
1999
with 3 others
Phase 1
46 of 142
none open now
Registered
82nd of 142
by date
Lead sponsor
123 of 142
Novo Nordisk A/S

Among the 142 studies testing Insulin Aspart in Diabetes Mellitus, this one is the 121st largest by enrollment, is one of 4 that started in 1999, is one of 46 in phase 1, and was the 82nd registered.

Diabetes Mellitus

8,295 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.

Browse Diabetes Mellitus studies →

Open to participants now

1 of the 142 studies testing Insulin Aspart in Diabetes Mellitus is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About Insulin Aspart

Insulin Aspart: first FDA approval 2000 (NOVOLOG PENFILL), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 649 Diabetes Mellitus studies recruiting now, 359 (55%) set no upper age limit and 194 (30%) stop at 75 or younger; 89 take children under 18; 181 take healthy volunteers.

This study: 18 Years to 50 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 142 studies testing Insulin Aspart in Diabetes Mellitus, or all of them as a file.
02

Study summary

This trial is conducted in Europe. The aim of this trial is to compare two formulations of biphasic insulin aspart 70 and characterise the pharmacokinetics of biphasic insulin aspart 50 and biphasic insulin aspart 70 in healthy male subjects.

Read the detailed description

Each subject participated in three treatment periods, and were randomly assigned to each of the six treatment sequences in varying order

03

Conditions studied

  • Diabetes
  • Healthy

Browse trials for

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Caucasian
  • Considered generally healthy upon completion of medical history and physical examination as judged by the Investigator
  • (BMI) between 19-27 kg/m\^2
  • Fasting plasma glucose between 3.8-6.0 mmol/L

Exclusion criteria

Exclusion Criteria:

  • Participation in any other clinical trial involving other products within the last three months
  • abnormal haematology or biochemistry screening tests, as judged by the Investigator
  • Any serious systemic infectious disease that occurred in the 4 weeks prior to the first dose of test drug
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    BIAsp 70 clinical trial formulation

    Drug: biphasic insulin aspart 70

  • Experimental
    BIAsp 70 final formulation

    Drug: biphasic insulin aspart 70

  • Experimental
    BIAsp 50 final formulation

    Drug: biphasic insulin aspart 50

Interventions

06

What researchers measure

Primary outcomes

  1. Area under the insulin aspart curve in the interval from 0-24 hours

Secondary outcomes

  1. Cmax, maximum insulin aspart concentration

  2. tmax, the time to maximum insulin aspart concentration

  3. t½, terminal half-life

  4. Cmin, minimum glucose concentration

  5. tmin, time to minimum concentration

07

Study locations

1 site
  • Novo Nordisk Investigational Site
    Leeds, LS2 9NG, United Kingdom
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 1999 to primary completion in Nov 1999, 0 months.

Of 171 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 10. This study's 0 months is below that.

Counting every sponsor, half of 247 studies reached it within 7 months; a quarter within 3 and three quarters within 17.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 25, 2012
First posted
Feb 1, 2012
StartActual
Nov 3, 1999
Primary completionActual
Nov 30, 1999
CompletionActual
Nov 30, 1999
Last update
Feb 24, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01523041
Lead sponsor
Novo Nordisk A/S
Responsible party
Sponsor
First posted
Feb 1, 2012
Start date
Nov 3, 1999
Primary completion
Nov 30, 1999
Completion
Nov 30, 1999
Last update
Feb 24, 2017

Study contacts

Global Clinical Registry (GCR, 1452)
study director · Novo Nordisk A/S

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Insulin Aspart

Start the discussion